Massachusetts Institute of Technology, 1986, BS
University of California, San Francisco, 1990, MD
- Hematopoietic cell transplantation for severe autoimmune diseases: Autologous and allogeneic transplantation for diseases including systemic sclerosis, multiple sclerosis and aplastic anemia.
- Nonmyeloablative hematopoietic cell transplantation: Regimens to reduce the toxicity of allogeneic transplantation, particularly in older patients or patients with medical comorbidities.
- Hematopoietic stem cell and T cell gene therapy: Laboratory-based studies on hematopoietic stem cell expansion and genetic correction of underlying disease.
- Development of radiation mitigators, for example, to reduce toxicity of gastrointestinal syndrome after irradiation.
- Hematopoietic cell transplantation for hematologic malignancies (leukemia, lymphoma and other malignancies) and autoimmune diseases (systemic sclerosis, multiple sclerosis and aplastic anemia).
- Treatment of acute and chronic graft-versus-host disease.
- Nonmyeloablative conditioning regimens for allogeneic hematopoietic cell transplantation
- Protocol 2260 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases
- Protocol 2533 A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis
- Protocol 2067 Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
- Protocol 1990 The Effect of Allogeneic Hematopoietic Cell Transplantation on the Activity and Progression of Multiple Sclerosis
- Protocol 1581 Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia – a Multi-Center Trial
- Protocol 1948 A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
- Protocol 1997 A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis
- “Increasing Stem Cell Numbers While Retaining Stem Cell Function” Ancillary/Collaborative Studies for the NHLBI Progenitor Cell Biology Consortium. Laboratory based project involving ex vivo expansion of CD34+ progenitor cells and gene marking.
- “Beclomethasone post-exposure therapy for gastrointestinal acute radiation syndrome” NIAID R43 AI100417